Serrated colonic lesions. Current review

Cover Page

Cite item

Full Text

Abstract

Serrated lesions, as a rule, were considered benign and were likened to hyperplastic polyps by anatomists and gastroenterologists. These views persisted until about 2010. However, recent data showed that serrated lesions can potentially transform into colorectal cancer (CRC). The World Health Organization classification identifies 4 categories of serrated lesions: hyperplastic polyps, sessile serrated lesions, traditional serrated adenoma and unclassified serrated adenomas. Sessile serrated lesions with dysplasia and traditional serrated adenomas are the most common precursors of CRC. Development of CRC from serrated lesions occurs through two different molecular pathways, namely, sporadic microsatellite instability and CpG island methylator phenotype, and the latter is considered the main mechanism inactivating serrated CRC pathway. In contrast to adenoma–carcinoma pathway, APC-inactivating mutations are rare in serrated adenomas.

About the authors

V. V. Vereshchak

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; S.S.Yudin City Clinical Hospital of the Moscow Healthcare Department

Author for correspondence.
Email: vvvereshchak@yandex.ru
ORCID iD: 0000-0002-6850-6919

Valeriya Vadimovna Vereshchak

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

4 Kolomenskiy proezd, Moscow 115446

Russian Federation

I. N. Iurichev

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-1345-041X

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

References

  1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7–30. doi: 10.3322/caac.21332
  2. Strum W.B. Colorectal adenomas. N Engl J Med 2016;374(11):1065–75. doi: 10.1056/NEJMra1513581
  3. Bettington M., Walker N., Rahman T. et al. High prevalence of sessile serrated adenomas in contemporary outpatient colonoscopy practice. Intern Med J 2017;47(3):318–23. doi: 10.1111/imj.13329
  4. Spring K.J., Zhao Z.Z., Karamatic R. et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006;131(5):1400–7. doi: 10.1053/j.gastro.2006.08.038
  5. Corley D.A., Jensen C.D., Marks A.R. et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370(14):1298–306. doi: 10.1056/NEJMoa1309086
  6. Schramm C., Janhsen K., Hofer J.H. et al. Detection of clinically relevant serrated polyps during screening colonoscopy: results from seven cooperating centers within the German colorectal screening program. Endoscopy 2018;50(10):993–1000. doi: 10.1055/a-0598-4477
  7. Lieberman D.A., Williams J.L., Holub J.L. et al. Race, ethnicity, and sex affect risk for polyps >9 mm in average-risk individuals. Gastroenterology 2014;147(2):351–8. doi: 10.1053/j.gastro.2014.04.037
  8. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H. et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370(14):1287–97. doi: 10.1056/NEJMoa1311194
  9. Longacre T.A., Fenoglio-Preiser C.M. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am J Surg Pathol 1990;14(6):524–37. doi: 10.1097/00000478-199006000-00003
  10. WHO Classification of Tumours of the Digestive System. 4th edn. International Agency for Research on Cancer. France, Lyon, 2010.
  11. WHO Classification of Tumors: DIGESTIVE System Tumours. 5th edn. International Agency for Research on Cancer. France, Lyon, 2019.
  12. Odze R.D. “Sessile Serrated Lesion”: the art and science of naming a disorder. Arch Pathol Lab Med 2021;145(10):1190–1. doi: 10.5858/arpa.2021-0134-LE
  13. Pai R.K., Bettington M., Srivastava A., Rosty C. An update on the morphology and molecular pathology of serrated colorectal polyps and associated carcinomas. Mod Pathol 2019;32(10):1390–415. doi: 10.1038/s41379-019-0280-2
  14. Torlakovic E.E., Gomez J.D., Driman D.K. et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am J Surg Pathol 2008;32(1):21–9. doi: 10.1097/PAS.0b013e318157f002
  15. East J.E., Saunders B.P., Jass J.R. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: сlassification, molecular genetics, natural history, and clinical management. Gastroenterol Clin N Am 2008;37(1):25–46. doi: 10.1016/j.gtc.2007.12.014
  16. Crockett S.D., Nagtegaal I.D. Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia. Gastroenterology 2019;157(4):949–6.e.4. doi: 10.1053/j.gastro.2019.06.041
  17. Sano W., Sano Y., Iwatate M. et al. Prospective evaluation of the proportion of sessile serrated adenoma/polyps in endoscopically diagnosed colorectal polyps with hyperplastic features. Endosc Int Open 2015;3(4):E354–8. doi: 10.1055/s-0034-1391948
  18. Iwatate M., Sano Y., Tanaka S. et al. Validation study for development of the Japan NBI Expert Team classification of colorectal lesions. Dig Endosc 2018;30(5):642–51. doi: 10.1111/den.13065
  19. Hazewinkel Y., de Wijkerslooth T.R., Stoop E.M. et al. Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. Endoscopy 2014;46(3):219–24. doi: 10.1055/s-0033-1358800
  20. Carr N.J., Mahajan H., Tan K.L. et al. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol 2009;62(6):516–8. doi: 10.1136/jcp.2008.061960
  21. Abdeljawad K., Vemulapalli K.C., Kahi C.J. et al. Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist. Gastrointest Endosc 2015;81(3):517–24. doi: 10.1016/j.gie.2014.04.064
  22. Wataru S., Daizen H., Akira T. et al. Serrated polyps of the colon and rectum: Remove or not? World J Gastroenterol 2020;26(19):2276–85. doi: 10.3748/wjg.v26.i19.2276
  23. Tadepalli U.S., Feihel D., Miller K.M. et al. A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). Gastrointest Endosc 2011;74(6):1360–8. doi: 10.1016/j.gie.2011.08.008
  24. Kimura T., Yamamoto E., Yamano H.O. et al. A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am J Gastroenterol 2012;107(3):460–9. doi: 10.1038/ajg.2011.457
  25. Yang J.F., Tang S.J., Lash R.H. et al. Anatomic distribution of sessile serrated adenoma/polyp with and without cytologic dysplasia. Arch Pathol Lab Med 2015;139(3):388–93. doi: 10.5858/arpa.2013-0523-OA
  26. Liu C., Walker N.I., Leggett B.A. et al. Sessile serrated adenomas with dysplasia: morphological patterns and correlations with MLH1 immunohistochemistry. Mod Pathol 2017;30(12):1728–38. doi: 10.1038/modpathol.2017.92
  27. Cenaj O., Gibson J., Odze R.D. Clinicopathologic and outcome study of sessile serrated adenomas/polyps with serrated versus intestinal dysplasia. Mod Pathol 2018;31(4):633–42. doi: 10.1038/modpathol.2017.169
  28. Bettington M.L., Walker N.I., Rosty C. et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol 2015;28(3):414–27. doi: 10.1038/modpathol.2014.122
  29. Sano W., Fujimori T., Ichikawa K. et al. Clinical and endoscopic evaluations of sessile serrated adenoma/polyps with cytological dysplasia. J Gastroenterol Hepatol 2018;33(8):1454–60. doi: 10.1111/jgh.14099
  30. Murakami T., Sakamoto N., Ritsuno H. et al. Distinct endoscopic characteristics of sessile serrated adenoma/polyp with and without dysplasia/carcinoma. Gastrointest Endosc 2017;85(3):590–600. doi: 10.1016/j.gie.2016.09.018
  31. Tate D.J., Jayanna M., Awadie H. et al. A standardized imaging protocol for the endoscopic prediction of dysplasia within sessile serrated polyps (with video). Gastrointest Endosc 2018;87(1):222–31.e.2. doi: 10.1016/j.gie.2017.06.031
  32. McCarthy A.J., Serra S., Chetty R. Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis. BMJ Open Gastroenterol 2019;6(1):120–2. doi: 10.1136/bmjgast-2019-000317
  33. Snover D.C., Jass J.R., Fenoglio-Preiser C., Batts K.P. Serrated polyps of the large intestine: а morphologic and molecular review of an evolving concept. Am J Clin Pathol 2005;124(3):380–91. doi: 10.1309/V2EP-TPLJ-RB3F-GHJL
  34. Sano Y., Saito Y., Fu K.I. et al. Efficacy of magnifying chromoendoscopy for the differential diagnosis of colorectal lesions. Dig Endosc 2005;17:105–16.
  35. Edelstein D.L., Axilbund J.E., Hylind L.M. et al. Serrated polyposis: rapid and relentless development of colorectal neoplasia. Gut 2013;62(3):404–8. doi: 10.1136/gutjnl-2011-300514
  36. Carballal S., Rodríguez-Alcalde D., Moreira L. et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut 2016;65(11):1829–37. doi: 10.1136/gutjnl-2015-309647
  37. IJspeert J.E., Rana S.A., Atkinson N.S. et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut 2017;66(2):278–84. doi: 10.1136/gutjnl-2015-310630
  38. MacPhail M.E., Thygesen S.B., Patel N. et al. Endoscopic control of polyp burden and expansion of surveillance intervals in serrated polyposis syndrome. Gastrointest Endosc 2019;90(1):96–100. doi: 10.1016/j.gie.2018.11.016
  39. Burt R. Inheritance of colorectal cancer. Drug Discov Today Dis Mech 2007;4(4):293–300. doi: 10.1016/j.ddmec.2008.05.004
  40. Nguyen H.T., Duong H.Q. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncol Lett 2018;16(1): 9–18. doi: 10.3892/ol.2018.8679
  41. Half E., Bercovich D., Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009;4:22. doi: 10.1186/1750-1172-4-22
  42. Lynch H.T., De la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348(10):919–32. doi: 10.1056/NEJMra012242
  43. Sinicrope F.A. Lynch syndrome-associated colorectal cancer. N Engl J Med 2018;379(8):764–73. doi: 10.1056/NEJMcp1714533
  44. Kastrinos F., Sapna S. Inherited colorectal cancer syndromes. Cancer J 2011;17(6):405–15. doi: 10.1097/PPO.0b013e318237e408
  45. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759–67. doi: 10.1016/0092-8674(90)90186-i
  46. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000;100(1):57–70. doi: 10.1016/s0092-8674(00)81683-9
  47. Grady W.M. Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 2005;33(Pt 4):684–8. doi: 10.1042/BST0330684
  48. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138(6):2073–87.e.3. doi: 10.1053/j.gastro.2009.12.064
  49. Gupta R., Sinha S., Paul R.N. The impact of microsatellite stability status in colorectal cancer. Curr Probl Cancer 2018;42(6):548–59. doi: 10.1016/j.currproblcancer.2018.06.010
  50. Pino M.S., Chung D.C. The chromosomal instability pathway in colon cancer. Gastroenterology 2010;138(6):2059–72. doi: 10.1053/j.gastro.2009.12.065
  51. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87(2):159–70. doi: 10.1016/s0092-8674(00)81333-1
  52. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361(25):2449–60. doi: 10.1056/NEJMra0804588
  53. Tsang A.H., Cheng K.H., Wong A.S. et al. Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. World J Gastroenterol 2014;20(14):3847–57. doi: 10.3748/wjg.v20.i14.3847
  54. Baker S.J., Fearon E.R., Nigro J.M. et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244(4901):217–21. doi: 10.1126/science.2649981
  55. Thiagalingam S., Lengauer C., Leach F.S. et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13(3):343–6. doi: 10.1038/ng0796-343
  56. Delker D.A., McGettigan B.M., Kanth P. et al. RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers. PLoS One 2014;9(2):e88367. doi: 10.1371/journal.pone.0088367
  57. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006;7(5):335–46. doi: 10.1038/nrm1907
  58. Pal T., Permuth-Wey J., Sellers T.A. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer 2008;113(4):733–42. doi: 10.1002/cncr.23601
  59. Ogino S., Nosho K., Kirkner G.J. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58(1):90–6. doi: 10.1136/gut.2008.155473
  60. Yamagishi H., Kuroda H., Imai Y., Hiraishi H. Molecular pathogenesis of sporadic colorectal cancers. Chin J Cancer 2016;35:4. doi: 10.1186/s40880-015-0066-y
  61. Hegde M., Ferber M., Mao R. et al. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYHassociated polyposis). Genet Med 2014;16(1):101–16. doi: 10.1038/gim.2013.166
  62. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50(1):113–30. doi: 10.1111/j.1365-2559.2006.02549.x
  63. Perucho M. Cancer of the microsatellite mutator phenotype. Biol Chem 1996;377(11):675–84.
  64. Mori Y., Yin J., Rashid A. et al. Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability. Cancer Res 2001;61(16):6046–9.
  65. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330–7. doi: 10.1038/nature11252
  66. Rex D.K., Ahnen D.J., Baron J.A. et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012;107(9):1315–30. doi: 10.1038/ajg.2012.161
  67. Patai A.V., Molnár B., Tulassay Z., Sipos F. Serrated pathway: Alternative route to colorectal cancer. World J Gastroenterol 2013;19(5):607–15. doi: 10.3748/wjg.v19.i5.607
  68. Leggett B., Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138(6):2088–100. doi: 10.1053/j.gastro.2009.12.066
  69. Nazemalhosseini Mojarad E., Kuppen P.J., Aghdaei H.A., Zali M.R. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench 2013;6(3):120–8.
  70. Lao V.V., Grady W.M. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8(12):686–700. doi: 10.1038/nrgastro.2011.173
  71. Toyota M., Ahuja N., Ohe-Toyota M. et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96(15):8681–6. doi: 10.1073/pnas.96.15.8681
  72. Hughes L.A., Khalid-de Bakker C.A., Smits K.M. et al. The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochim Biophys Acta 2012;1825(1):77–85. doi: 10.1016/j.bbcan.2011.10.005
  73. Yokoi K., Harada H., Yokota K. et al. Epigenetic status of CDO1 gene may reflect chemosensitivity in colon cancer with postoperative adjuvant chemotherapy. Ann Surg Oncol 2019;26(2):406–14. doi: 10.1245/s10434-018-6865-z
  74. Kokelaar R.F., Jones H., Beynon J. et al. Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer. Int J Colorectal Dis 2018;33(8):995–1000. doi: 10.1007/s00384-018-3108-5
  75. Hawkins N., Norrie M., Cheong K. et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002;122(5):1376–87. doi: 10.1053/gast.2002.32997
  76. Shen L., Catalano P.J., Benson A.B. 3rd et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007;13(20):6093–8. doi: 10.1158/1078-0432.CCR-07-1011
  77. Ogino S., Cantor M., Kawasaki T. et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55(7):1000–6. doi: 10.1136/gut.2005.082933
  78. Weisenberger D.J., Siegmund K.D., Campan M. et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38(7):787–93. doi: 10.1038/ng1834
  79. Ogino S., Kawasaki T., Kirkner G.J. et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007;9(3):305–14. doi: 10.2353/jmoldx.2007.060170
  80. O’Brien M.J., Yang S., Mack C. et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 2006;30(12):1491–501. doi: 10.1097/01.pas.0000213313.36306.85.
  81. Mezzapesa M., Losurdo G., Celiberto F. et al. Serrated colorectal lesions: an up-to-date review from histological pattern to molecular pathogenesis. Int J Mol Sci 2022;23(8):4461. doi: 10.3390/ijms23084461

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.